XLV Deep Dive — U.S. Healthcare Sector ETF, In-Depth Analysis

① Overview

XLV (Health Care Select Sector SPDR Fund) is the leading US healthcare-sector ETF, launched by State Street in December 1998. It holds only the healthcare companies in the S&P 500 on a market-cap-weighted basis, giving one-shot exposure to the pharmaceutical, biotech, medical-device, healthcare-services, and life-science-tools industries. It holds 59 names with a 0.08% expense ratio — among the lowest in its category — and a Morningstar overall rating of ★★★★. (Source: SSGA Fact Sheet, as of 2026-03-31 / accessed 2026-06-15)

In plain terms: A "sector ETF" bundles many companies in one industry (here, healthcare) into a single product. Instead of picking one drugmaker, you put 59 large US healthcare companies in one basket to spread the risk.

② Top 10 Holdings

Top 10 holdings total ~59.1%. (Source: SSGA Fact Sheet, as of 2026-03-31 / accessed 2026-06-15)

③ Cost · Tracking · Tax

A 0.08% expense ratio is about $8 per year on a $10,000 investment — very cheap on cost alone. But for a Korean investor, the true all-in cost must add the price-to-NAV trading gap and US dividend tax (15% withholding when a W-8BEN is filed) on top of the expense ratio. Since distributions reduce after-tax returns, "low cost = low burden" is an oversimplification. (Source: SSGA Fact Sheet, as of 2026-03-31 / accessed 2026-06-15)

④ Performance — This Year's Trend and Long-Term Returns

This year (2026), XLV has traded in a range. From 154.87 at the start of the year it peaked at 159.54 on Feb 27, then slid to 142.84 on Apr 29 (~-10.5% from the peak), before recovering to 153.81 by Jun 15. Year-to-date it is about -0.7%, trailing both SPY (+8.9%) and XLP (consumer staples, +11.1%) over the same period. (Source: Supabase etf_prices, 2026-01-02–2026-06-15)

Long-term annualized returns are +5.96% (1Y), +6.36% (3Y), and +9.83% (5Y). (Source: SSGA Fact Sheet, NAV basis, 2026-03-31 / accessed 2026-06-15)

⑤ Risks

Sector·stock concentration (myth-buster): There's a perception that "healthcare is safe because it's spread across 59 names," but in reality the top 10 holdings make up ~59% of the fund, the top 5 ~42%, and just two names — Eli Lilly and J&J — about 25%. By industry, pharmaceuticals alone are 37.1%, close to half, so XLV is effectively driven by the performance of a handful of large pharma stocks. (Source: SSGA Fact Sheet, 2026-03-31)

Policy·regulatory risk: Drug-price cuts, changes to medical reimbursement, and patent expirations (the patent cliff) hit pharma stocks directly. The higher the pharma weight, the greater the exposure.

FX·relative-performance risk: As a US ETF, KRW/USD moves flow straight through to won-denominated returns. And in a risk-on regime like this year's, defensive healthcare can lag the broad market (SPY) or growth sectors.

⑥ Three Comparable ETFs

(Source: each issuer — Vanguard·Fidelity·iShares, accessed 2026-06-15)

The key difference is "breadth and cost." XLV holds only 59 large-caps — more concentrated but very cheap — while VHT·FHLC spread across 400+ names, though the big moves are still led by the same large pharma stocks. IYH has a similar structure but a fee roughly 5x higher, making it less cost-efficient.

This post is part of an analytical process built on the AI four-model debate system and public data. MC AI Labs tracks its calls and returns under the principle of "we disclose even when we are wrong." This content is for informational purposes and is not investment advice recommending the purchase or sale of any specific stock or ETF. Investment decisions and responsibility rest with the investor.

Auto-translated. This English edition was generated from the Korean original by Claude. Past performance does not guarantee future results. Not investment advice.